Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HRMY
stocks logo

HRMY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
237.99M
+18.24%
0.850
-0.01%
221.69M
+20.01%
0.857
+9.86%
243.11M
+21.26%
0.973
+43.04%
Estimates Revision
The market is revising Upward the revenue expectations for Harmony Biosciences Holdings, Inc. (HRMY) for FY2025, with the revenue forecasts being adjusted by 2.52% over the past three months. During the same period, the stock price has changed by 6.28%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.52%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.27%
In Past 3 Month
Stock Price
Go Up
up Image
+6.28%
In Past 3 Month
Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 46.00 USD with a low forecast of 32.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 46.00 USD with a low forecast of 32.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 38.250
sliders
Low
32.00
Averages
46.00
High
62.00
Current: 38.250
sliders
Low
32.00
Averages
46.00
High
62.00
Mizuho
Graig Suvannavejh
Outperform
maintain
$36 -> $39
2025-11-06
Reason
Mizuho
Graig Suvannavejh
Price Target
$36 -> $39
2025-11-06
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Harmony Biosciences to $39 from $36 and keeps an Outperform rating on the shares following the Q3 report. The firm cites the strong Wakix performance for the target increase.
BofA
Underperform
maintain
$31 -> $32
2025-11-04
Reason
BofA
Price Target
$31 -> $32
2025-11-04
maintain
Underperform
Reason
BofA raised the firm's price target on Harmony Biosciences to $32 from $31 and keeps an Underperform rating on the shares after the company reported Q3 results after having pre-announced last week. The firm notes that its revised sales forecast reflects a slightly higher near-term launch ramp and FY25 mid-point guidance increase of 2%, adding that it raised Wakix forecasts 2%-3% in 2025-27.
Mizuho
NULL -> Outperform
maintain
$35 -> $36
2025-10-29
Reason
Mizuho
Price Target
$35 -> $36
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Harmony Biosciences to $36 from $35 and keeps an Outperform rating on the shares.
UBS
Buy
downgrade
$50 -> $43
2025-10-15
Reason
UBS
Price Target
$50 -> $43
2025-10-15
downgrade
Buy
Reason
UBS lowered the firm's price target on Harmony Biosciences to $43 from $50 and keeps a Buy rating on the shares. Investor concerns over Harmony Biosciences have intensified following Zygel's Phase 3 failure and the IH approval setback, while upcoming orexin agonists threaten Wakix's market position, the analyst says.
H.C. Wainwright
Buy
downgrade
$70 -> $55
2025-09-25
Reason
H.C. Wainwright
Price Target
$70 -> $55
2025-09-25
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Harmony Biosciences to $55 from $70 and keeps a Buy rating on the shares. The firm removed ZYN002 from its model after the Phase 3 RECONNECT trial missed the endpoint.
Mizuho
Outperform
to
NULL
downgrade
$50 -> $35
2025-09-25
Reason
Mizuho
Price Target
$50 -> $35
2025-09-25
downgrade
Outperform
to
NULL
Reason
Mizuho lowered the firm's price target on Harmony Biosciences to $35 from $50 and keeps an Outperform rating on the shares. The firm cites the company's negative Phase data for ZYN002 in fragile X syndrome for the target cut. However, Mizuho still sees a favorable risk/reward for the shares given the optionality with Harmony's remaining pipeline.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY.O) is 10.27, compared to its 5-year average forward P/E of 18.55. For a more detailed relative valuation and DCF analysis to assess Harmony Biosciences Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
18.55
Current PE
10.27
Overvalued PE
29.76
Undervalued PE
7.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.11
Undervalued EV/EBITDA
5.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.01
Current PS
0.00
Overvalued PS
5.76
Undervalued PS
2.27
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 246.27% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 18208.08% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 246.27% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HRMY News & Events

Events Timeline

(ET)
2025-12-01
07:19:00
Mizuho Raises Harmony Biosciences Price Target to $46, Maintains Outperform Rating
select
2025-11-24 (ET)
2025-11-24
08:16:13
Harmony Biosciences Reveals Findings from Pitolisant Bioequivalence Study
select
2025-11-04 (ET)
2025-11-04
08:10:23
Harmony Biosciences Announces Q3 Earnings Per Share of $1.08, Exceeding Consensus Estimate of 86 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedHarmony Biosciences Set to Unveil New Phase 3 Trial Data for EPX-100 in Dravet Syndrome Next Week

  • Upcoming Presentation: Harmony Biosciences will present new open-label extension data from its ARGUS trial at the American Epilepsy Society Annual Meeting on December 8, 2025.

  • Trial Details: The ARGUS trial is a phase 3 study assessing the efficacy and safety of EPX-100 for treating Dravet syndrome, involving a 4-week observational period, a 16-week double-blind period, and an open-label extension lasting up to 156 weeks.

  • Drug Background: EPX-100, initially developed by Epygenix Therapeutics, was integrated into Harmony's pipeline following its acquisition of Epygenix in April 2024.

  • Market Performance: Harmony Biosciences' stock has fluctuated between $25.52 and $40.93 over the past year, closing at $36.01, reflecting a 1.41% increase on the last trading day.

[object Object]
Preview
4.0
12-01Benzinga
Mizuho Keeps Outperform Rating for Harmony Biosciences Holdings and Increases Price Target to $46

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

[object Object]
Preview
9.0
11-24NASDAQ.COM
Harmony Biosciences Announces Encouraging Outcomes for Pitolisant GR; Aims to Submit NDA in Early 2026

  • Bioequivalence Study Results: Harmony Biosciences announced that its pitolisant gastro-resistant formulation is bioequivalent to the marketed pitolisant tablet, with both containing 17.8 mg of the active ingredient.

  • Dosing Optimization Findings: A dosing-optimization study indicated that all patients could begin treatment at the therapeutic dose of 17.8 mg without the need for dose titration.

  • Future Plans for Drug Application: The company plans to submit a new drug application for the pitolisant GR formulation in early 2026, aiming for a PDUFA date in the first quarter of 2027.

  • Market Response: Following the announcement, Harmony Biosciences shares saw a slight increase of 0.32% in pre-market trading, reaching $34.42.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY) stock price today?

The current price of HRMY is 38.25 USD — it has increased 3.38 % in the last trading day.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY)'s business?

Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

arrow icon

What is the price predicton of HRMY Stock?

Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 46.00 USD with a low forecast of 32.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY)'s revenue for the last quarter?

Harmony Biosciences Holdings Inc revenue for the last quarter amounts to 239.46M USD, increased 28.71 % YoY.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY)'s earnings per share (EPS) for the last quarter?

Harmony Biosciences Holdings Inc. EPS for the last quarter amounts to 0.87 USD, increased 10.13 % YoY.

arrow icon

What changes have occurred in the market's expectations for Harmony Biosciences Holdings Inc (HRMY)'s fundamentals?

The market is revising Upward the revenue expectations for Harmony Biosciences Holdings, Inc. (HRMY) for FY2025, with the revenue forecasts being adjusted by 2.52% over the past three months. During the same period, the stock price has changed by 6.28%.
arrow icon

How many employees does Harmony Biosciences Holdings Inc (HRMY). have?

Harmony Biosciences Holdings Inc (HRMY) has 246 emplpoyees as of December 05 2025.

arrow icon

What is Harmony Biosciences Holdings Inc (HRMY) market cap?

Today HRMY has the market capitalization of 2.20B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free